“Big money” Positions

“Big money sentiment for Incyte Corp (NASDAQ:INCY) in 2018 Q4 decreased to 0.96, according to SEC filings. So its down -0.23, from 2018Q3’s 1.19. 169 active investment managers increased and started new positions, while 176 cut down and sold their holdings in Incyte Corp so the sentiment turned negative. These funds own 188.24 million shares, that’s up from 180.88 million shares in 2018Q3. Funds holding Incyte Corp in top 10 decreased from 5 to 4 for a decrease of 1. 51 Investors Sold All; 125 Reduced Holdings; 117 increased holdings while 52 active investment managers bought holdings.

Biggest Incyte Corp Investors

As of 2018 Q4 Baker Bros. Advisors Lp has 17.83% invested in Incyte Corp. As of 2018 Q4, 1.30 million shares of Incyte Corp are owned by Davide Leone & Partners Investment Co Llp. Furthermore, Bb Biotech Ag reported 3.81 million shares in Incyte Corp equivalent to 7.76% of its fund portfolio. The Norway-based fund Sector Gamma As have invested about 3.6% of the active investment manager’s stock portfolio in Incyte Corp. The New York-based fund Pura Vida Investments Llc looks positive on Incyte Corp, owning 55,207 shares.

Incyte Corporation focuses on the discovery, development, and commercialization of proprietary therapeutics in oncology in the United States and internationally.The company has $18.01 billion market cap. It offers JAKAFI for the treatment of myelofibrosis and polycythemia vera cancers.164.94 is the P/E ratio. The companyÂ’s clinical stage products include ruxolitinib cream that is in Phase II clinical trial for the treatment of alopecia areata and atopic dermatitis; and baricitinib, which is in Phase III clinical trial for treatment of rheumatoid arthritis.

INCY touched $84.12 during the last trading session after $0.94 change.Currently Incyte Corporation is uptrending after 2.79% change in last March 14, 2018. INCY has also 461,811 shares volume. INCY underperformed by 1.58% the S&P500.

Investors expect Incyte Corporation (NASDAQ:INCY)’s quarterly earnings on May, 7., according to Faxor. Analysts have expectation on stock’s EPS of $0.23. That’s up 227.78 % from last year’s $-0.18 EPS. This could reach $49.23M profit for INCY assuming the current $0.23 EPS will become reality. After $0.35 EPS was announced previous quarter, analysts now see negative EPS growth of -34.29 % for Incyte Corporation.

Metropolitan Life Insurance Company New York holds 34,590 shs. The New York-based Barrett Asset Management Lc has invested 0% in Incyte Corporation (NASDAQ:INCY). 5,855 are held by Prelude Cap Limited. Cornerstone Advisors holds 0% or 124 shs in its capital. Employees Retirement System Of Texas owns 60,000 shs for 0.06% of their capital. Gabelli Funds Limited Co invested 0.02% in Incyte Corporation (NASDAQ:INCY). Barclays Public Ltd Com holds 0.02% or 393,804 shs. 781,967 are held by Deutsche Comml Bank Ag. New York State Teachers Retirement Sys has invested 0.04% of its capital in Incyte Corporation (NASDAQ:INCY). Dekabank Deutsche Girozentrale, Germany-based fund reported 110,493 shs. Bnp Paribas Asset Mgmt Sa invested 0% of its capital in Incyte Corporation (NASDAQ:INCY). M&T Financial Bank Corporation reported 10,434 shs. Pub Sector Pension Board owns 0% invested in Incyte Corporation (NASDAQ:INCY) for 9,035 shs. State Street Corporation reported 7.62M shs stake. Da Davidson has 7,795 shs.

Incyte Corporation had 10 selling transactions and 1 insider purchase since October 3, 2018. This’s net activity of $7.51 million. On Tuesday, January 8 Flannelly Barry P had sold 1,714 shs worth $129,510. On Friday, January 4 Trower Paul also sold $689,025 worth of Incyte Corporation (NASDAQ:INCY). SWAIN PAULA J had sold 30,000 shs worth $2.10M on Friday, January 4. On Thursday, November 8 BIENAIME JEAN JACQUES bought $68,765 worth of Incyte Corporation (NASDAQ:INCY) or 1,000 shs.

Incyte Corporation (NASDAQ:INCY) Ratings Coverage

In total 10 analysts cover Incyte (NASDAQ:INCY). “Buy” rating has 5, “Sell” are 0, while 5 are “Hold”. 50% are bullish. 13 are the (NASDAQ:INCY)’s analyst reports since September 25, 2018 according to StockzIntelligence Inc. On Monday, October 22 the firm has “Neutral” rating given by Cantor Fitzgerald. On Thursday, February 14 Oppenheimer maintained Incyte Corporation (NASDAQ:INCY) with “Hold” rating. On Thursday, January 3 the firm has “Buy” rating given by Guggenheim. On Thursday, February 14 the rating was maintained by Cantor Fitzgerald with “Hold”. The company rating was downgraded by UBS on Wednesday, January 16. The company rating was upgraded by Gabelli on Thursday, January 24. On Monday, February 25 the company was maintained by Argus Research. On Thursday, February 14 the firm has “Buy” rating by Piper Jaffray given. On Thursday, January 24 William Blair upgraded Incyte Corporation (NASDAQ:INCY) to “Outperform” rating.

For more Incyte Corporation (NASDAQ:INCY) news brought out briefly go to: Nasdaq.com, Nasdaq.com, Nasdaq.com, Seekingalpha.com or Nasdaq.com. The titles are as follows: “4 Toxic Stocks to Abandon or Sell Short for Solid Gains – Nasdaq” brought out on March 13, 2019, “Merck Gets Priority Review for Keytruda Combo in Kidney Cancer – Nasdaq” on February 18, 2019, “Notable ETF Inflow Detected – QQEW, I, CELG, INCY – Nasdaq” with a publish date: February 13, 2019, “Incyte Corporation 2018 Q4 – Results – Earnings Call Slides – Seeking Alpha” and the last “Incyte (INCY) Q4 Earnings Lag Estimates – Nasdaq” with publication date: February 14, 2019.